Elucidating the mechanisms of additive effects at high concentrations on hydrophobic interaction chromatography.


Journal

Journal of chromatography. A
ISSN: 1873-3778
Titre abrégé: J Chromatogr A
Pays: Netherlands
ID NLM: 9318488

Informations de publication

Date de publication:
02 Aug 2023
Historique:
received: 04 03 2023
revised: 17 05 2023
accepted: 19 05 2023
medline: 6 6 2023
pubmed: 4 6 2023
entrez: 3 6 2023
Statut: ppublish

Résumé

Hydrophobic interaction chromatography (HIC) is a commonly used chromatography technique for purifying proteins. It utilizes salting-out salts to facilitate the binding of native proteins to weakly hydrophobic ligands. There have been three proposed mechanisms for the promoting effects of salting-out salts, which include the dehydration of proteins by salts, cavity theory, and salt exclusion. To evaluate the above three mechanisms, an HIC study was conducted on Phenyl Sepharose using four different additives. These additives included a salting-out salt (NH

Identifiants

pubmed: 37269642
pii: S0021-9673(23)00317-5
doi: 10.1016/j.chroma.2023.464091
pii:
doi:

Substances chimiques

Salts 0
Proteins 0
Sodium Chloride 451W47IQ8X
Polyethylene Glycols 3WJQ0SDW1A

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

464091

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest This work was supported by Kyokuto Pharmaceutical Industrial Co., Ltd. Y.T., Y.K. and T.A. (Teruo Akuta) are employees of the for-profit company Kyokuto Pharmaceuticals. T.A. (Tsutomu Arakawa) used to belong to the for-profit company Alliance Protein Laboratories but currently has no conflict of interest.

Auteurs

Tsutomu Arakawa (T)

Alliance Protein Laboratories, 13380 Pantera Rd, San Diego, CA 92130, USA. Electronic address: tarakawa2@aol.com.

Yui Tomioka (Y)

Research and Development Division, Kyokuto Pharmaceutical Industrial Co., Ltd., 3333-26, Aza-Asayama, Kamitezuna Takahagi-shi, Ibaraki 318-0004, Japan.

Yasunori Kurosawa (Y)

Research and Development Division, Kyokuto Pharmaceutical Industrial Co., Ltd., 3333-26, Aza-Asayama, Kamitezuna Takahagi-shi, Ibaraki 318-0004, Japan.

Teruo Akuta (T)

Research and Development Division, Kyokuto Pharmaceutical Industrial Co., Ltd., 3333-26, Aza-Asayama, Kamitezuna Takahagi-shi, Ibaraki 318-0004, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH